The retention compounds, which are considered recompounds, which normally are secreted into the urine results sponsible for the uremic syndrome, are uremic toxins. (5) identification, characterization, analytical determination and evaluation of biological activity of uremic retention solutes.
conform to a true definition of uremic toxins. Uremic patients develop atheromatotic vascular disease more frequently and identified and accurate quantitative analysis in biological earlier than the general population. The classical risk factors fluids should be possible; (2) the total body and plasma seem to be less important. Other factors have been suggested levels should be higher in uremic than in nonuremic to be at play, and among those uremic toxins are mentioned subjects. (3) high concentrations should be related to as potential culprits. The identification, classification and charspecific uremic dysfunctions and/or symptoms that deacterization of the solutes responsible for vascular problems seems of utmost importance but is far from complete due crease or disappear when the concentration is reduced; to a lack of standardization and organization. The European (4) biological activity, conforming to clinical changes obUremic Toxin Work Group (EUTox) has as a primary aim to served in conjunction with the uremic syndrome, should discuss, analyze and offer guidelines in matters related to the be proven in in vivo, ex vivo, or in vitro studies; and (5) identification, characterization, analytical determination and evaluation of biological activity of uremic retention solutes.
concentrations in these studies should conform to those
The final aim remains the development of new strategies to found in body fluids or tissue of uremic patients [5] .
reduce the concentration of the most active uremic solutes.
Obviously, only a few of the uremic retention solutes These activities will at first be concentrated on reducing factors fully conform to the definition of a true uremic toxin, influencing cardiovascular morbidity and mortality. and even those might be a matter of debate (e.g., H 2 O, phosphate, potassium, ␤ 2 -microglobulin). One of the ma-DEFINITIONS jor problems arising in this area is that many of the Since many decades, the problem of uremic toxicity compounds with a presumed or proven biologic potential has been a major area of concern for the entire nephroare difficult to remove by conventional dialysis, either belogic community. The retention in the body of comcause of their molecular weight and/or as a consequence pounds that normally are secreted into the urine by the of their protein binding. As a result, number 3 of the healthy kidneys gives rise to a progressive deterioration above-mentioned conditions is especially difficult to corof physiologic functions and of the clinical condition.
roborate. On the other hand, if clinical proof of benefit The resulting clinical picture is the uremic syndrome.
by removal remains absent, the impetus for researchers If uremic retention solutes are considered as such withor industries to produce devices or other methodologies out necessarily proven toxicity, at least 90 organic comof potential help for the removal of these molecules pounds have been retained in uremia [1] . The most imusually remains minimal. This results in a vicious circle, portant known organic uremic retention solutes are whereby technologic/pharmacologic innovations to relisted in Table 1 . To this list should be added a number move solutes other than the classic compounds, such as of inorganic substances, such as water, potassium, phosurea, are limited or even nonexistent. phate, and the trace elements [2] [3] [4] . This is probably only the tip of the iceberg, and many more still unidentified UREA AS A UREMIC RETENTION SOLUTE/ solutes are possibly retained and might exert toxicity.
UREMIC TOXIN
One of the most typical examples of the sometimes- presently known uremic retention solutes the highest The global experience regarding urea teaches us that concentration in uremic serum. It has been used as a uremic toxicity is neither a question of retention of urea marker of uremic retention and removal for several years alone, nor of water-soluble compounds alone; in the [6] , and its removal is directly related to patient survival treatment of the uremic syndrome, hence, more than the [7] . Nevertheless, there are very few studies demonstraremoval of urea alone should be pursued. It should be ting a direct biologic impact of urea at currently encounrealized that urea removal is not representative for many tered uremic concentrations [8] , and those studies show other molecules, and that this is especially the case for an impact that not necessarily concentrates on key orhard to remove molecules, such as protein-bound solutes ganic functions in the biochemical/biologic status of the or the middle molecules (Ͼ500 daltons) [12] . Many of human body.
these molecules exert biologic and/or clinical acivities When urea was added to the dialysate during a period [8] . Among the few small water-soluble uremic retention of several months at concentrations largely exceeding compounds that have been shown to exert biologic acthose currently encountered in dialyzed uremics, uremic tion, many again have an intradialytic kinetic behavior symptomatology was not consistently altered over the that is indisputably different from that of urea (e.g., the entire study period [9] , again suggesting that by itself, guanidines, phosphate, xanthine, and hypoxanthine [13]). urea is not very important in the development of uremic Cardiovascular morbidity and mortality as toxicity.
a uremic problem It is difficult to explain the apparent paradox between the validity of urea as a marker and its presumed lack Uremic patients develop atheromatotic vascular disease more frequently and earlier than the general population of toxicity. Of note, urea removal seems to be related as a surrogate marker only indirectly to survival, and not [14, 15] . The classic risk factors affecting the general population, such as hypercholesterolemia or hypertension, to quality of life. One possibility to consider is that urea removal by itself does not affect survival, but that it is seem to have less weight in the development of vascular problems in uremia [16, 17] . Other elements have been representative for the removal of one or more other solutes with a more consistent impact. One such potential suggested to be at play, and among those, uremic toxins have been mentioned as potential culprits [17] . Dialytic culprit is potassium, another small-water soluble compound known to substantially affect dialytic survival [4] . treatment seems to have no major impact on the evolution of this process. The latter observation indicates that the Another possibility is that, together with urea, other uremic solutes antagonizing its toxic impact are retained current concept of dialysis, with major emphasis on removal of water-soluble compounds, is insufficient to pre-[10]. Finally, urea might be at the origin of other, more toxic moieties, such as some of the guanidines or carbavent or slow down cardiovascular damage. In line with this observation, scattered studies based on different methodmylation products [8, 11] .
S-8
ologies and evaluating different solutes show that most, review of the presently known uremic retention solutes was recently finalized and submitted; this publication if not all, compounds which up until now have been suggested to play a role in atherogenesis, show a dialytic contains a classification according to solute characteristics, and information about their concentration (see bebehavior which is different from that of urea: advanced glycation end products (AGEs), advanced oxidation prolow) [1] . In June 2002, an Expression of Interest (EoI) was submitted to the European Community in the contein products (AOPP), homocysteine, phosphate, asymmetric dimethylarginine (ADMA), and cytokines [5] .
text of the 6th Framework Program (FP-6). Currently, the group is involved in the definition of standardized Hence, the identification, classification, and characterization of the clinical importance of the solutes responsievaluation procedures for in vitro and in vivo research (inclusive high through-put and proteome analysis). ble for cardiovascular morbidity and mortality is of utmost importance to improve survival and quality of life More information on the intentions and structure can be obtained from the web site of the group: http://www. of the uremic population before and after the start of dialysis. Only subsequent to this can the development uremic-toxins.org. The review of the existing retention solutes is based of specific devices pursuing the removal of those compounds be launched. Finally, the possibility should be on a literature search of 857 publications, of which 141 deal with concentration [1] . Those publications appeared considered that the same factors might be at play in the general population.
in the literature from 1968 to 2002. To compose the final lists, information from 55 publications covering 90 solThis search for the responsible solutes is, however, flawed by a number of confounding factors, especially for utes was used, and the resulting tables display the mean (median) concentration in the normal population, the in vitro studies: (1) the difficulty to define adequate measures to guarantee purity of samples (prevention of conmean (median) concentration in the uremic population (highest reported value), the highest single concentration tamination with lipopolysaccharides or other contaminants); (2) the lack of a systematic coordinated approach ever reported, and the molecular weight. This publica-(up until now, several research groups applied differently tion offers a guideline regarding the concentrations to prepared compounds in different experimental set-ups be pursued for future in vitro or in vivo studies. at incorrect concentrations, not conforming to those enSolutes were subdivided into small water-soluble comcountered in clinical uremia); and (3) the lack of considpounds (non-protein-bound), protein-bound compounds, eration of intermutual influences among various solutes and middle molecules. Sixty-eight molecules had a MW when they are present together in the uremic milieu. Ͻ500 daltons, whereas 22 compounds were classified as It is of note that those problems are not specific for middle molecules (Ͼ500 daltons). Twelve molecules had uremic toxin research in the area of cardiovascular coma molecular weight in excess of 12,000 daltons. Twentyplications, but that they are equally relevant for any other five solutes were protein bound; these were mostly small aspect of the uremic syndrome (e.g., uremic anemia, compounds with a MW Ͻ500 daltons but included also progression of the loss of residual renal function, etc.). the middle molecules leptin and retinol-binding protein.
Concentrations range from ng/L (methionine-enkephaThe European Uremic Toxin Work Group (EUTox)
lin) up to g/L (urea). While recognizing the problems related to an insuffiThis review further contains reflections on the interinciently coordinated approach in the area of uremic toxin dividual variability of these concentrations (e.g., the ratio research, the European Uremic Toxin Work Group between uremic and normal concentration, the scatter (EUTox) started its activities in the autumn of 2000. This of concentrations in the uremic population, and the difgroup is made up of several European researchers who ferences in concentration among various publications). have been active in this field for many years, together Indisputably, such a list will necessitate regular updatwith representatives of the major industries active in ing, with the introduction of newly detected compounds, dialysis treatment. This group was installed under the as well as newly defined concentrations of already known auspices of the European Society for Artificial Organs compounds. The plan is to display the lists on the web (ESAO).
site of the Work Group, where it will be made possible The primary aim of this group is to discuss, analyze, to contact the Work Group concerning newly identified and offer guidelines in matters related to the identificasolutes and/or concentrations which are aberrant from tion, characterization, analytical determination, and evalthose reported in the Work Group's lists. uation of biologic activity of uremic retention solutes. The Work Group has accomplished and is working on MODIFICATIONS IN THE THERAPEUTIC/ a number of projects. In October 2001, a common text PREVENTIVE APPROACH endorsed by all members of the group presenting a state While extending our knowledge about solutes responof the art in the area of uremic toxicity, especially in relation to cardiovascular events, was published [5] . A sible for the uremic syndrome, the final aim remains the 
